All In Biotech

Drug Trial Radar · NCT05805501

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 199 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

199

Actual

Start

Apr 21, 2023

Primary completion

Oct 5, 2026

Study completion Oct 5, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Apr 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).

Conditions

  • Renal Cell Carcinoma

Interventions

  • TobemstomigDrug

    Participants will receive IV tobemstomig Q3W.

  • TiragolumabDrug

    Participants will receive IV tiragolumab Q3W.

  • PembrolizumabDrug

    Participants will receive IV pembrolizumab Q3W.

  • AxitinibDrug

    Participants will receive axitinib PO BID.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Adverse Events (AEs)Time frame: Up to a maximum of 2 years

Locations

42 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • UC Irvine Medical Center

    Orange, California

  • Emory University

    Atlanta, Georgia

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • UT Southwestern Medical Center

    Dallas, Texas

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia

  • Beijing Cancer Hospital

    Beijing, China

  • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

    Nanjing, China

  • Tianjin Cancer Hospital

    Tianjin, China

  • Institut Sainte Catherine

    Avignon, France

  • CHU Besançon - Hôpital Jean Minjoz

    Besançon, France

  • CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre

    Bordeaux, France

  • Centre Francois Baclesse

    Caen, France

  • Centre Leon Berard

    Lyon, France

  • Institut Gustave Roussy

    Villejuif, France

  • Universitätsklinikum "Carl Gustav Carus"

    Dresden, Germany

  • Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II

    Hamburg, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Klinikum rechts der Isar der TU München

    München, Germany

  • Studienpraxis Urologie

    Nürtingen, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny

    Brzozów, Poland

  • Centrum Onkologii im. Prof. Franciszka ?ukaszczyka

    Bydgoszcz, Poland

  • Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii

    Krakow, Poland

  • Szpital Kliniczny im. Heliodora ?wi?cickiego UM w Poznaniu

    Późna, Poland

  • National Cancer Center

    Goyang-si, South Korea

  • Chonnam National University Hwasun Hospital

    Jeollanam-do, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Hospital Universitario Clínico San Carlos

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Cordoba, Spain

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.